EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, SAB Biotherapeutics's Enterprise Value is $-13.76 Mil.
SAB Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.32 Mil. Therefore, SAB Biotherapeutics's EV-to-FCF for today is 0.54.
The historical rank and industry rank for SAB Biotherapeutics's EV-to-FCF or its related term are showing as below:
SABS'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.2 Med: -1.59 Max: 0.92
Current: 0.51
During the past 5 years, the highest EV-to-FCF of SAB Biotherapeutics was 0.92. The lowest was -5.20. And the median was -1.59.
SABS's EV-to-FCF is ranked better than 76.55% of 388
companies
in the Biotechnology industry
Industry Median: 6.5
vs SABS: 0.51
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for SAB Biotherapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SAB Biotherapeutics's EV-to-FCF
For the Biotechnology subindustry, SAB Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SAB Biotherapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where SAB Biotherapeutics's EV-to-FCF falls into.
SAB Biotherapeutics's current Enterprise Value is $-13.76 Mil.
SAB Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAB Biotherapeutics (NAS:SABS) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
SAB Biotherapeutics's PE Ratio for today is calculated as:
SAB Biotherapeutics's share price for today is $4.01.
SAB Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.740.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SAB Biotherapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of SAB Biotherapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
SAB Biotherapeutics (SAB Biotherapeutics) Business Description
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SABS has been successfully added to your 